{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:33:39Z","timestamp":1793360019158,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sydnexis Inc"},{"name":"Santen SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40123-026-01341-0","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:44:24Z","timestamp":1774266264000},"page":"1685-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03%"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-5525","authenticated-orcid":false,"given":"Michael","family":"Korenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1741-5067","authenticated-orcid":false,"given":"Maria","family":"Hurcikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-6468","authenticated-orcid":false,"given":"Kay","family":"Tatsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-7065","authenticated-orcid":false,"given":"Dana","family":"Tomcikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-5375","authenticated-orcid":false,"given":"Janet","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3086-0677","authenticated-orcid":false,"given":"Marek","family":"Kacerik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the STAR Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"1341_CR1","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft DI, He M, Jonas JB, et al. IMI\u2014defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20\u201330.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"1341_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036\u201342.","journal-title":"Ophthalmology"},{"issue":"3","key":"1341_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo-2024-325427","volume":"109","author":"J Liang","year":"2025","unstructured":"Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109(3):362\u201371.","journal-title":"Br J Ophthalmol"},{"key":"1341_CR4","volume-title":"Webvision: the organization of the retina and visual system","author":"BJ Carr","year":"1995","unstructured":"Carr BJ, Stell WK. The science behind myopia. In: Kolb H, Fernandez E, Jones B, Nelson R, editors. Webvision: the organization of the retina and visual system. Salt Lake City: University of Utah Health Sciences Center; 1995."},{"issue":"2","key":"1341_CR5","first-page":"116","volume":"112","author":"M Recko","year":"2015","unstructured":"Recko M, Stahl ED. Childhood myopia: epidemiology, risk factors, and prevention. Mo Med. 2015;112(2):116\u201321.","journal-title":"Mo Med"},{"key":"1341_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12186062","author":"N Mart\u00ednez-Albert","year":"2023","unstructured":"Mart\u00ednez-Albert N, Bueno-Gimeno I, Gen\u00e9-Sampedro A. Risk factors for myopia: a review. J Clin Med. 2023;12(18):6062.","journal-title":"J Clin Med"},{"issue":"9","key":"1341_CR7","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1167\/iovs.07-1451","volume":"49","author":"JM Ip","year":"2008","unstructured":"Ip JM, Rose KA, Morgan IG, Burlutsky G, Mitchell P. Myopia and the urban environment: findings in a sample of 12-year-old Australian school children. Invest Ophthalmol Vis Sci. 2008;49(9):3858\u201363.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1341_CR8","doi-asserted-by":"crossref","unstructured":"Atowa U, Hansraj R, Wajuihian S. Vision problems: a review of prevalence studies on refractive errors in school-age children. Afr Vision Eye Health. 2019;78(1):a461.","DOI":"10.4102\/aveh.v78i1.461"},{"issue":"11","key":"1341_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561\u201379.","journal-title":"Ophthalmology"},{"issue":"6","key":"1341_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/bjophthalmol-2020-316234","volume":"106","author":"JR Polling","year":"2022","unstructured":"Polling JR, Klaver C, Tideman JW. Myopia progression from wearing first glasses to adult age: the DREAM study. Br J Ophthalmol. 2022;106(6):820.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1341_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s40123-024-00951-w","volume":"13","author":"LS Eppenberger","year":"2024","unstructured":"Eppenberger LS, Grzybowski A, Schmetterer L, Ang M. Myopia control: are we ready for an evidence based approach? Ophthalmol Ther. 2024;13(6):1453\u201377.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"1341_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1341_CR13","first-page":"1171","volume":"106","author":"J Bao","year":"2022","unstructured":"Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022;106(8):1171\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1341_CR14","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1167\/iovs.12-10565","volume":"53","author":"P Cho","year":"2012","unstructured":"Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53(11):7077\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1341_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/02713683.2016.1221979","volume":"42","author":"J Santodomingo-Rubido","year":"2017","unstructured":"Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Guti\u00e9rrez-Ortega R, Sugimoto K. Long-term efficacy of orthokeratology contact lens wear in controlling the progression of childhood myopia. Curr Eye Res. 2017;42(5):713\u201320.","journal-title":"Curr Eye Res"},{"issue":"8","key":"1341_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","volume":"96","author":"P Chamberlain","year":"2019","unstructured":"Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556\u201367.","journal-title":"Optom Vis Sci"},{"issue":"5","key":"1341_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00417-018-3906-z","volume":"256","author":"A Ruiz-Pomeda","year":"2018","unstructured":"Ruiz-Pomeda A, P\u00e9rez-S\u00e1nchez B, Valls I, Prieto-Garrido FL, Guti\u00e9rrez-Ortega R, Villa-Collar C. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):1011\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"1341_CR18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2015.10803","volume":"314","author":"M He","year":"2015","unstructured":"He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA. 2015;314(11):1142\u20138.","journal-title":"JAMA"},{"issue":"6","key":"1341_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/aos.13403","volume":"95","author":"S Xiong","year":"2017","unstructured":"Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551\u201366.","journal-title":"Acta Ophthalmol"},{"key":"1341_CR20","doi-asserted-by":"publisher","first-page":"105988","DOI":"10.1016\/j.ypmed.2020.105988","volume":"132","author":"CA Enthoven","year":"2020","unstructured":"Enthoven CA, Tideman JWL, Polling JR, Yang-Huang J, Raat H, Klaver CCW. The impact of computer use on myopia development in childhood: the Generation R study. Prev Med. 2020;132:105988.","journal-title":"Prev Med"},{"issue":"4","key":"1341_CR21","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.62347\/GZUA2622","volume":"17","author":"M Xu","year":"2025","unstructured":"Xu M, Zhang F. Advances in optical and pharmacological strategies for myopia correction in children. Am J Transl Res. 2025;17(4):2422\u201333.","journal-title":"Am J Transl Res"},{"issue":"12","key":"1341_CR22","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"W-H Chua","year":"2006","unstructured":"Chua W-H, Balakrishnan V, Chan Y-H, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285\u201391.","journal-title":"Ophthalmology"},{"issue":"2","key":"1341_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012;119(2):347\u201354.","journal-title":"Ophthalmology"},{"issue":"2","key":"1341_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"1341_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324.","journal-title":"Ophthalmology"},{"issue":"4","key":"1341_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697\u2013708.","journal-title":"Ophthalmology"},{"key":"1341_CR27","doi-asserted-by":"crossref","unstructured":"Pirenzepine. In: Aronson JK, editor. Meyler\u2019s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier; 2006. p. 2842.","DOI":"10.1016\/B0-44-451005-2\/00602-1"},{"issue":"4","key":"1341_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jaapos.2007.10.014","volume":"12","author":"RM Siatkowski","year":"2008","unstructured":"Siatkowski RM, Cotter SA, Crockett RS, Miller JM, Novack GD, Zadnik K. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008;12(4):332\u20139.","journal-title":"J AAPOS"},{"issue":"6","key":"1341_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","volume":"49","author":"K Richdale","year":"2023","unstructured":"Richdale K, Skidmore KV, Tomiyama ES, Bullimore MA. Compounded 0.01% atropine-what\u2019s in the bottle? Eye Contact Lens. 2023;49(6):219\u201323.","journal-title":"Eye Contact Lens"},{"key":"1341_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040588","author":"H Austermann","year":"2021","unstructured":"Austermann H, Schaeffel F, Mathis U, et al. Corneal penetration of low-dose atropine eye drops. J Clin Med. 2021;10(4):588.","journal-title":"J Clin Med"},{"issue":"3","key":"1341_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens. 2020;46(3):129\u201335.","journal-title":"Eye Contact Lens"},{"issue":"7","key":"1341_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","volume":"22","author":"RMC Di Martino","year":"2023","unstructured":"Di Martino RMC, Maxwell BD, Pirali T. Deuterium in drug discovery: progress, opportunities and challenges. Nat Rev Drug Discov. 2023;22(7):562\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"1341_CR33","first-page":"149","volume-title":"Refraction and motility","author":"WB Lancaster","year":"1952","unstructured":"Lancaster WB. Refraction and motility. Charles C Thomas: Springfield; 1952. p. 149."},{"issue":"1","key":"1341_CR34","doi-asserted-by":"publisher","first-page":"e0210387","DOI":"10.1371\/journal.pone.0210387","volume":"14","author":"HS Kim","year":"2019","unstructured":"Kim HS, Yu DS, Cho HG, Moon BY, Kim SY. Comparison of predicted and measured axial length for ophthalmic lens design. PLoS One. 2019;14(1):e0210387.","journal-title":"PLoS One"},{"issue":"3","key":"1341_CR35","first-page":"382","volume":"9","author":"YM Wang","year":"2022","unstructured":"Wang YM, Lu SY, Zhang XJ, Chen LJ, Pang CP, Yam JC. Myopia genetics and heredity. Children (Basel). 2022;9(3):382.","journal-title":"Children (Basel)"},{"issue":"6","key":"1341_CR36","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.apjo.2024.100122","volume":"13","author":"E Zaabaar","year":"2024","unstructured":"Zaabaar E, Zhang Y, Kam KW, et al. Low-concentration atropine for controlling myopia onset and progression in East Asia. Asia Pac J Ophthalmol. 2024;13(6):100122.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"4","key":"1341_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1197\/j.aem.2003.06.014","volume":"11","author":"JG Schier","year":"2004","unstructured":"Schier JG, Ravikumar PR, Nelson LS, Heller MB, Howland MA, Hoffman RS. Preparing for chemical terrorism: stability of injectable atropine sulfate. Acad Emerg Med. 2004;11(4):329\u201334.","journal-title":"Acad Emerg Med"},{"issue":"2","key":"1341_CR38","first-page":"CD014758","volume":"2","author":"JG Lawrenson","year":"2023","unstructured":"Lawrenson JG, Shah R, Huntjens B, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):CD014758.","journal-title":"Cochrane Database Syst Rev"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01515-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01341-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:01:33Z","timestamp":1793358093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01341-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01341-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The online version of this article was revised because the sentence beginning \u201cChildren receiving \u2026\u201d in the Plain Language Summary was incorrect. Now, the it has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01515-w","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01515-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Korenfeld, MD, is a paid consultant for Santen Inc and Sydnexis. Maria Hurcikova: no conflicts of interest. Kay Tatsuoka is an employee of Santen Inc. Dana Tomcikov\u00e1: no conflicts of interest. Janet Cheetham is a consultant for Sydnexis, and owns stock in AbbVie, Merck, and Johnson & Johnson. Marek Kacerik: no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and informed consents\/assents were approved by the required institutional review boards or ethics committees, and the study was conducted in accordance with Good Clinical Practice guidelines and tenets of the Declaration of Helsinki. Before any protocol-required procedure, written informed consent was obtained from parents or legal guardians; participants 6\u00a0years and above provided self-assent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}